CAR T-Cells & NK Cells

In this product category, you will find reports and other services providing you with the most uptodate business and competitive intelligence information on chimeric antigen receptor (CAR) T-cells and natural killer (NK) cells. The range of products covers industry data as well as in-depth strategic assessment and analysis of engineered CAR T-cell and NK cell technologies, targets, companies and R&D pipeline.

Subscribe to
our newsletters!

Showing all 1 result

  • May of 2019
    This report provides an overview of CD33-targeted antibody and cell therapies in development for treatment of acute myeloid leukemia (AML)